Introduction {#s1}
============

Gene expression analysis is becoming more important in diagnostic fields as it allows for the identification of novel biomarkers relevant to diseases. Endogenous reference genes (ERGs) are widely used to normalize the mRNA level in the relative quantification to provide an accurate comparison of gene expression between different samples [@pone.0006162-Vandesompele1]. Traditional ERGs (tERGs), such as *GAPDH* and *ACTB*, have been used in expression studies without proper validation because of the assumption that they are expressed at constant levels across different samples and regardless of experimental treatments [@pone.0006162-Thellin1], [@pone.0006162-Bustin1]. However, several reports have shown that the expression of tERGs can vary in different tissues and be regulated by experimental treatments or pathological state [@pone.0006162-Thellin1], [@pone.0006162-Tricarico1]--[@pone.0006162-Hamalainen1]. As the use of inappropriate ERGs in relative quantification of gene expression can result in biased expression profiles [@pone.0006162-Tricarico1], [@pone.0006162-Dheda1], [@pone.0006162-deKok1], the selection of proper ERGs is essential for accurate measurement especially in quantitative methods including qRT-PCR, which is a highly sensitive and accurate method [@pone.0006162-Huggett1].

Although there have been a number of previous studies aimed at finding suitable ERGs, most of them have focused on selecting the most stable genes from commonly used ERGs [@pone.0006162-Goidin1]--[@pone.0006162-Radonic1]. Moreover, the identification of novel ERGs (nERGs) has been based primarily on microarray data [@pone.0006162-Hamalainen1], [@pone.0006162-Hoerndli1]--[@pone.0006162-Shulzhenko1]. Although short-oligo microarrays such as Affymetrix GeneChips, have the advantage of being highly sensitive in detecting low abundance transcripts (nearly 3--20 transcripts per million (tpm)) [@pone.0006162-Lipshutz1], they have some disadvantages such as inaccurate cross hybridization between probes and transcripts, differences in hybridization efficiencies between probe sets, limited linear range of signal, and incorrect annotation of transcripts [@pone.0006162-Haverty1], [@pone.0006162-vanRuissen1]. Therefore, an approach using only microarray data may not be sufficient to identify the most suitable ERGs. Although an ideal universal ERG may not exist [@pone.0006162-Vandesompele1], [@pone.0006162-Haller1], a combination of large expression data from different platforms is expected to complement the limitation of each platform [@pone.0006162-Sun1] and allow for the identification of more suitable ERGs.

Here, we describe an algorithm for the identification of nERGs using the publicly available human gene expression datasets in addition to in-house microarray data. The expression of selected nERGs in datasets was validated by qRT-PCR in 108 human samples and their expression stability was compared to that of tERGs.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

This study was approved by the institutional review board of Samsung Medical Center. Patients\' written informed consent was not required to be obtained as the institutional review board approved the use of human tissues in this study without patients\' consent with the reason that the data were analyzed anonymously and patients could not be identified.

EST, SAGE, microarray gene expression dataset construction {#s2b}
----------------------------------------------------------

EST and SAGE human gene expression data were collected from the publicly available Cancer Genome Anatomy Project (CGAP) site (<http://cgap.nci.nih.gov/>). Microarray data was obtained from the Cancer Genome Expression Database of LG Life Sciences, which is based on the Affymetrix HG-U133 (for the samples included in microarray data, see [Table S1](#pone.0006162.s003){ref-type="supplementary-material"})[@pone.0006162-Lee2]. A detailed description of each dataset construction is provided in the Supplementary Materials and Methods ([Text S1](#pone.0006162.s001){ref-type="supplementary-material"}) and shown schematically in [Figure 1](#pone-0006162-g001){ref-type="fig"}.

![Flowchart of the methodology for identification of nERGs.\
2,087 candidate HKGs were first identified by selecting the genes meeting the following criteria: 0\'s prop \<0.4 in EST, \<0.1 in shortSAGE and \<0.3 in longSAGE. 0\'s prop represents 0\'s proportion (number of tissues in which the gene is not expressed/total number of tissues, 0≤0\'s prop≤1). Among the candidate 2,087 HKGs, 13 nERGs with the lowest CVs were further identified by selecting the genes common to all four datasets among the genes with the 400 lowest CVs (approximately 20% of candidate HKGs).](pone.0006162.g001){#pone-0006162-g001}

Algorithm for the identification of candidate HKGs and 13 nERGs {#s2c}
---------------------------------------------------------------

The methodology used to identify nERGs is outlined in [Figure 1](#pone-0006162-g001){ref-type="fig"}. First, to identify nERGs, we searched for candidate HKGs whose expression is detected in most tissues using 0\'s proportion in EST and SAGE datasets. 0\'s proportion is defined as the proportion of different tissues in which a given gene is not expressed and was calculated as follows:

In this equation a value of 0 indicates that the gene is expressed in all tissues, and a value of 1 indicates that the gene is not expressed in any tissue. If a gene was expressed in any one library of multiple libraries corresponding to the same tissue, that gene was considered to be expressed in that tissue. A total of 2,087 candidate HKGs with low 0\'s proportions in all three datasets were selected ([Table S2](#pone.0006162.s004){ref-type="supplementary-material"}). Cut-off values for 0\'s proportion in each dataset were determined to include the majority of the 575 HKGs identified from a previous Affymetrix U95A chip [@pone.0006162-Eisenberg1] (see [Figure 1](#pone-0006162-g001){ref-type="fig"}, [Text S1](#pone.0006162.s001){ref-type="supplementary-material"}). Affymetrix (Affy) data for 5,317 probe sets corresponding to 2,087 HKGs were obtained. Mean gene expression and CV (%) for each gene were calculated in each dataset. The Student\'s t-test was used to assess whether the mean gene expression between candidate HKGs and non-HKGs was statistically different. When this set of 2,087 HKGs was classified functionally using the Functional Classification Catalogue (FunCat, Version 2.0) [@pone.0006162-Ruepp1], known functions were available for only 1,318 genes of them (for details, see [Text S1](#pone.0006162.s001){ref-type="supplementary-material"}). For CpG island analysis, sequences upstream of the annotated transcription start site of RefSeq genes were obtained from the UCSC site and CpG islands in their upstream sequences were searched using the CpGIE software [@pone.0006162-Wang1]. The statistical significance of differences in the frequency of genes with CpG islands between HKGs and non-HKGs was determined using Z-test (R program, <http://www.R-project.org>). *P*\<0.05 was considered to be significantly different.

Among the 2,087 HKGs, potential ERGs were further identified according to the following process: 1) the CV was calculated for each UniGene cluster and 2) the genes in each dataset were ranked by ascending CV values. Among the first 400 genes with the lowest CVs (approximately 20% of 2,087 HKGs), we found 13 nERGs common to all four datasets (i.e. EST, LongSAGE, ShortSAGE, and Affy). The CV values between tERGs and nERGs were compared using Wilcoxon rank sum test.

Genomic variations of nERGs and tERGs {#s2d}
-------------------------------------

The Database of Genomic Variants (<http://projects.tcag.ca/variation/>) was used to search for genomic variations of the 2,087 HKGs, including nERGs and tERGs.

RNA preparation from human frozen, FFPE tissues and human cancer cell lines and qRT-PCR {#s2e}
---------------------------------------------------------------------------------------

The Department of Pathology at Samsung Medical Center provided 26 human frozen tissues and 60 FFPE tissues and the Korea Cell Line Bank (KCLB) or ATCC provided 22 human cancer cell lines ([Table S3](#pone.0006162.s005){ref-type="supplementary-material"}). The 60 FFPE tissues consisted of 10 breast cancers, 8 normal stomach, 9 stomach cancers, 10 normal ovaries, 4 ovarian adenomas, 9 ovarian borderline tumors and 10 ovarian cancers.

Total RNA isolation and cDNA synthesis from human samples are described in detail in the Supplementary Materials and Methods ([Text S1](#pone.0006162.s001){ref-type="supplementary-material"}). Total RNA from frozen tissues and cell lines was isolated using Trizol (Invitrogen Life Technologies). The inclusion criteria for the RNA samples were A260/280≥1.80 and rRNA (28S/18S) ratio≥1.0. The integrity of RNA from frozen tissues and cell lines was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA). Paradise Whole Transcript RT Reagent system (Arcturus, CA, USA) was used for RNA isolation and RT of FFPE tissues.

PCR primers and Universal Probe Library (UPL) numbers for this study are provided in [Table 1](#pone-0006162-t001){ref-type="table"}. Primers and probes for each gene were designed to have a short amplicon size. All PCR reactions were performed in a Lightcycler 2.0 (Roche Applied Science) according to standard procedures (for details, see [Text S1](#pone.0006162.s001){ref-type="supplementary-material"}). PCR efficiency for each gene in frozen tissues and cell lines was determined by both the serial dilution method using Lightcycler 4.0 software and estimation using the LinRegPCR program [@pone.0006162-Ramakers1] ([Table 1](#pone-0006162-t001){ref-type="table"}, [Text S1](#pone.0006162.s001){ref-type="supplementary-material"}). To minimize experimental variation, the same gene in different samples was tested in the same PCR run.

10.1371/journal.pone.0006162.t001

###### Real-time PCR primers and Taqman probes used in this study.

![](pone.0006162.t001){#pone-0006162-t001-1}

  Gene Symbol                              Title                                 Accession number      Probe[\*](#nt101){ref-type="table-fn"} (UPL Probe No.)                 Primer                  Amplicon size (bp)   PCR efficiency (dilution)[\*\*](#nt102){ref-type="table-fn"}   PCR efficiency (LinRegPCR)[\*\*\*](#nt103){ref-type="table-fn"}
  ------------- ------------------------------------------------------------ ------------------------ -------------------------------------------------------- ------------------------------------- -------------------- -------------------------------------------------------------- -----------------------------------------------------------------
  GAPDH                   Glyceraldehyde-3-phosphate dehydrogenase                  NM_002046                                    60                                 Left 18 agccacatcgctcagaca                66                                      1.899                                                      1.735±0.048 (137)
                                                                                                                                                                   Right 19 gcccaatacgaccaaatcc                                                                                          
  ACTB                                  Actin, beta                                 NM_001101                                    64                                 Left 18 ccaaccgcgagaagatga                97                                      2.038                                                      1.491±0.034 (137)
                                                                                                                                                                   Right 20 ccagaggcgtacagggatag                                                                                         
  B2M                               Beta-2-microglobulin                            NM_004048                                    42                                 Left 19 ttctggcctggaggctatc               86                                      1.868                                                      1.717±0.068(140)
                                                                                                                                                                 Right 23 tcaggaaatttgactttccattc                                                                                        
  PPIA                   Peptidylprolyl isomerase A (cyclophilin A)                 NM_021130             Specific Probe[\#](#nt104){ref-type="table-fn"}         Left 22 catctgcactgccaagactgag             326                                      1.877                                                      1.773±0.058(142)
                                                                                                                                                                   Right 19 tgcaatccagctaggcatg                                                                                          
  HPRT1                   Hypoxanthine phosphoribosyltransferase 1                  NM_000194                                    73                              Left 24 tgaccttgatttattttgcatacc            102                                      1.800                                                      1.771±0.024 (143)
                                                                                                                                                                   Right 20 cgagcaagacgttcagtcct                                                                                         
  HMBS                          Hydroxymethylbilane synthase                        NM_000190                                    26                                 Left 18 tgtggtgggaaccagctc                92                                      1.954                                                      1.431±0.031(143)
                                                                                                                                                                   Right 19 tgttgaggtttccccgaat                                                                                          
  TBP                             TATA box binding protein                          NM_003194                                    3                                 Left 20 gctggcccatagtgatcttt               60                                      1.826                                                      1.447±0.038(142)
                                                                                                                                                                  Right 21 cttcacacgccaagaaacagt                                                                                         
  H6PD                        Hexose-6-phosphate dehydrogenase                      NM_004285                                    89                               Left 23 tggagatcatcatgaaagagacc             74                                      1.874                                                      1.832±0.026 (64)
                                                                                                                                                                   Right 20 gcgaatgacaccgtactcct                                                                                         
  ZNF207                          Zinc finger protein 207                           NM_003457                                    27                                Left 21 ctgtttcctagcacagcacaa              65                                      1.869                                                      1.648±0.018 (142)
                                                                                                                                                                 Right 23 ggtttgaaatctgtaccaacagg                                                                                        
  OAZ1                       Ornithine decarboxylase antizyme 1                     NM_004152                                    74                                 Left 18 caccatgccgctcctaag                67                                      2.068                                                      1.498±0.059(142)
                                                                                                                                                                   Right 20 gagggagaccctggaactct                                                                                         
  LUC7L2                        LUC7-like 2 (S. cerevisiae)                         NM_016019                                    85                                Left 20 cgatcacacagcaagaatcc               60                                      1.829                                                      1.709±0.047 (143)
                                                                                                                                                                   Right 19 agatcgatgtctgcgatgc                                                                                          
  CTBP1                         C-terminal binding protein 1                  NM_001012614 NM_001328                             77                                 Left 18 actgcgtgaccctgcact                86                                      2.064                                                      1.651±0.055 (141)
                                                                                                                                                                    Right 18 gccccttgtctcatctgc                                                                                          
  TRIM27                       Tripartite motif containing 27                  NM_006510 NM_030950                               7                                  Left 19 caggcacgagctgaactct               71                                      1.908                                                      1.693±0.034 (143)
                                                                                                                                                                   Right 20 agctgctcaaactcccaaac                                                                                         
  GPBP1                      GC-rich promoter binding protein 1                     NM_022913                                    4                                 Left 21 tcacttgaggcagaacacaga              75                                      1.844                                                      1.715±0.031 (141)
                                                                                                                                                                 Right 23 agcacatgtttcatcattttcac                                                                                        
  UBQLN1                                Ubiquilin 1                                 NM_013438                                    73                                Left 20 gaatcctgaccttgctgcac               92                                      1.864                                                      1.723±0.027(143)
                                                                                                                                                                  Right 21 ttgggagctgttgtctcattt                                                                                         
  ARL8B                       ADP-ribosylation factor-like 8B                       NM_018184                                    82                                 Left 19 aagcatgtgggagcggtat               66                                      1.838                                                      1.499±0.074(139)
                                                                                                                                                                  Right 22 cgatctgcagcatctatcatgt                                                                                        
  PAPOLA                          Poly(A) polymerase alpha                          NM_032632                                    78                                Left 21 gctacgaagaccagtccattg              91                                      1.830                                                      1.509±0.032(141)
                                                                                                                                                                   Right 20 tgttggtcacagatgctgct                                                                                         
  CUL1                                    Cullin 1                                  NM_003592                                    65                                 Left 18 gcgaggtcctcactcagc                86                                      1.810                                                      1.695±0.027(139)
                                                                                                                                                                Right 26 ttctttctcaattagaatgtcaatgc                                                                                      
  DIMT1L         DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)          NM_014473                                    77                             Left 27 tccagtgttgtaaggatagaacctaag           75                                      1.906                                                      1.655±0.037(141)
                                                                                                                                                                 Right 23 ccttactagaccatcccattcct                                                                                        
  FBXW2                       F-box and WD-40 domain protein 2                      NM_012164                                    3                                  Left 19 cggctctgcagacttcact              111                                      1.891                                                       1.638±0.02(142)
                                                                                                                                                                  Right 22 ttgcacttctgcaaaactacct                                                                                        
  SPG21          Spastic paraplegia 21 (autosomal recessive, Mast syndrome)         NM_016630                                    21                                Left 20 gatgtctttttccggcagat               88                                      1.826                                                      1.636±0.021(142)
                                                                                                                                                                  Right 21 cgagatggtcccaataaactg                                                                                         

UPL probes were designed using Probe Finder in the Universal Probe Library (UPL) Assay Design Center (Roche Applied Science, Mannheim, Germany).

PCR efficiency for each gene was determined by using serial dilutions of cDNA from MKN 74 cells for PCR and then calculating the efficiency using the Roche Lightcycler software 4.0.

PCR efficiencies of 48 samples in triplicate were calculated using LinRegPCR (Ramakers et al. Neurosci Lett, 2003. **339**(1): p. 62--6.).

**F-**ttcttgctggtcttgccat**T**cctgga-**p** (T, TAMRA-labeled; F, FAM-labeled; P, Phosphate).

Gene expression stability analysis in qRT-PCR {#s2f}
---------------------------------------------

To analyze gene expression stability, we used the geNorm v.3.4 [@pone.0006162-Vandesompele1] and NormFinder software [@pone.0006162-Andersen1]. Cp values were converted into relative quantities for analysis with geNorm and NormFinder, taking into consideration the PCR efficiencies of the genes, as shown in [Table 1](#pone-0006162-t001){ref-type="table"} (for details, see [Text S1](#pone.0006162.s001){ref-type="supplementary-material"}). The optimal number of ERGs for normalization was also determined using the geNorm program. The statistical differences in gene expression stability values between nERGs and tERGs were determined using Wilcoxon rank sum test. The Pearson and Spearman correlation between the gene expression stability calculated by geNorm or NormFinder (M for geNorm and S for NormFinder) and the CV calculated in each dataset were analyzed using R statistical software. *P*\<0.05 was considered to be significant.

Results {#s3}
=======

Identification and characterization of 2,087 candidate HKGs {#s3a}
-----------------------------------------------------------

2,087 candidate HKGs were first identified using 0\'s proportion in each dataset ([Figure 1](#pone-0006162-g001){ref-type="fig"}, [Table S2](#pone.0006162.s004){ref-type="supplementary-material"}). According to the functional classification by FunCat [@pone.0006162-Ruepp1], genes with a variety of basic cellular functions were included in this list. In particular, proteins mediating protein fate (23%) and cellular transport (21%) had the highest frequency ([Figure 2A](#pone-0006162-g002){ref-type="fig"}). This is in contrast to the previously reported classifications of HKGs, in which metabolic and ribosomal proteins were enriched [@pone.0006162-Eisenberg1], [@pone.0006162-Hsiao1]. We compared the frequency of genes with CpG islands in the upstream sequences of transcription start sites in HKGs relative to non-HKGs. Most HKGs (70%) were found to possess a CpG island within 1,000 bp from the transcription start site, consistent with previous studies [@pone.0006162-Larsen1], [@pone.0006162-Ponger1], while fewer CpG islands were found in the upstream sequences of non-HKGs (*P*\<0.001) ([Table 2](#pone-0006162-t002){ref-type="table"}). Mean expression level of HKGs was significantly higher than that of non-HKGs in all datasets (*P*\<0.001) ([Figure 2B](#pone-0006162-g002){ref-type="fig"}), also consistent with previous work [@pone.0006162-Eisenberg1] (for detailed description on the expression of 2,087 HKGs in 4 datasets, see [Text S2](#pone.0006162.s002){ref-type="supplementary-material"}). CV values of the 2,087 genes showed a poor correlation between the four datasets, whereas gene expression showed a relatively higher correlation ([Table S4](#pone.0006162.s006){ref-type="supplementary-material"}).

![Characterization of candidate HKGs identified in this study.\
(A) The functional distribution of candidate HKGs was classified by FunCat. Among the 2,087 UniGene clusters, a total of 1,605 UniGene clusters which have GO terms under biological processes were classified according to their major functional categories using FunCat (version 2.0) by mapping the GO terms to FunCat categories. A total of 1,318 UniGene clusters were classified by FunCat. The number of UniGene clusters belonging to each category is presented in A. In some cases, UniGene clusters mapped to two or more FunCat categories. (B) Comparison of gene expression between candidate HKGs and non-HKGs in each dataset. Box and Whisker plots provide a simple description of a distribution of values by depicting the 25^th^ and 75^th^ percentile values as the bottom and top of a box, respectively. The Y axis represents the natural logarithm transformed mean gene expression levels. The median expression values of HKGs and non-HKGs are marked by horizontal lines in the boxes and the values are provided to the right of each box. \**P*\<0.001.](pone.0006162.g002){#pone-0006162-g002}

10.1371/journal.pone.0006162.t002

###### Comparison of the proportion of genes with CpG islands in sequences upstream of the transcription start site in HKGs and non-HKGs.

![](pone.0006162.t002){#pone-0006162-t002-2}

           HKGs (n = 2,002)[\*](#nt105){ref-type="table-fn"}   Non-HKGs (n = 14,848)[\*\*](#nt106){ref-type="table-fn"}               
  ------- --------------------------------------------------- ---------------------------------------------------------- ------- ---- ---------
  5,000                          1,516                                                    76                              8,036   54   \<0.001
  2,000                          1,456                                                    73                              7,410   50   \<0.001
  1,000                          1,410                                                    70                              7,048   47   \<0.001

Of 2,087 genes, 2,002 UniGene clusters corresponded to upstream sequences downloaded from the UCSC site (<http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/>).

A total of 16,850 UniGene clusters corresponded to upstream sequences downloaded from the UCSC site and the number of non-HKGs was calculated by subtracting the 2,002 HKGs from the total 16,850.

CpG island criteria: length≥500 bp, % GC≥55, CpG o/e ratio≥0.65.

Identification and characterization of 13 nERGs {#s3b}
-----------------------------------------------

A total of 13 nERGs common to the four datasets (*ZNF207, OAZ1, LUC7L2, CTBP1, TRIM27, GPBP1, ARL8B, UBQLN1, PAPOLA, CUL1, DIMT1L, FBXW2*, and *SPG21*, [Table 3](#pone-0006162-t003){ref-type="table"}) were identified from 2,087 HKGs. The highest proportion (5/13) (*ZNF207, OAZ1, CTBP1, PAPOLA, FBXW2*) of genes were genes involved in cellular metabolism. CpG islands were found in the upstream region from transcription start site of all 13 nERGs ([Table S5](#pone.0006162.s007){ref-type="supplementary-material"}).

10.1371/journal.pone.0006162.t003

###### nERGs identified from four datasets.
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  UniGene cluster    Gene Symbol                           Gene Title                            EST     SHORT SAGE   LONG SAGE   Affymetrix   Gene Ontology                                                                                                                                                                                                           
  ----------------- ------------- ------------------------------------------------------------ -------- ------------ ----------- ------------ --------------- ------- -------- ------- ------- -------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------
  Hs.446427             OAZ1                   Ornithine decarboxylase antizyme 1               673.68     62.71        0.069       576.39         55.94         0     444.92   41.01     0     1860.9   22.07                                                                  Polyamine biosynthesis                                                                                         Ornithine decarboxylase inhibitor activity
  Hs.9589              UBQLN1                             Ubiquilin 1                           111.34     60.19        0.31        75.93          61.3        0.036   71.77    49.75   0.111   919.32   26.81                                                                                                                                                                                               Kinase binding
  Hs.444279             GPBP1                  GC-rich promoter binding protein 1               132.98     56.92        0.241       63.11          61.65         0     80.72    51.79   0.111   746.56   26.6                                                                                                                                                          
  Hs.208597             CTBP1                     C-terminal binding protein 1                  136.74     48.53        0.138       213.99         62.01         0     112.96   50.6      0     481.51   24.72                               Negative regulation of cell proliferation; Protein phosphorylation; Viral genome replication                                               Protein C-terminus binding; Transcription factor binding
  Hs.253726            PAPOLA                       Poly(A) polymerase alpha                    216.15     65.36        0.172       118.24         58.02         0      89.5    50.88     0     451.23   27.68                                                                   mRNA polyadenylation                                                                                                          RNA binding
  Hs.250009             ARL8B                   ADP-ribosylation factor-like 8B                 132.27     55.79        0.379       134.21         61.55         0     59.19    55.14   0.111   418.28   26.81                                                                  Chromosome segregation                                                                       α-tubulin binding;β-tubulin binding; GDP binding; GTP binding; GTPase activity
  Hs.242458             SPG21      Spastic paraplegia 21 (autosomal recessive, Mast syndrome)   120.35     59.44        0.31        76.41          57.83       0.036    73.3    49.12     0     415.64   29.35                                                       Antigen receptor-mediated signaling pathway                                                                                          CD4 receptor binding
  Hs.530118            LUC7L2                     LUC7-like 2 (S. cerevisiae)                   132.76     59.55        0.172       74.65          65.41         0     57.21    50.39   0.111   386.79   22.9                                                                                                                                                          
  Hs.500775            ZNF207                       Zinc finger protein 207                     233.29     62.27        0.034       165.68         56.77         0     154.32   52.88   0.111   358.69   18.38                                                        Regulation of transcription, DNA-dependent                                                                             Transcription factor activity; Zinc ion binding
  Hs.533222            DIMT1L      DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)    129.17     69.14        0.379       42.41          60.55       0.071   36.87    44.13   0.111   164.72   28.3                                                                                                                                                          
  Hs.440382            TRIM27                    Tripartite motif containing 27                 155.33     68.54        0.172       80.66          63.06         0     67.84    45.41   0.111   163.6    26.3                                                            Cell proliferation; Spermatogenesis                                                                   Metal ion binding; Transmembrane receptor protein tyrosine kinase activity
  Hs.146806             CUL1                                Culin 1                             120.27      57.5        0.207       69.33          65.76       0.036   76.43     55     0.111   156.47   27.78   Cell cycle arrest; G1/S transition of mitotic cell cycle; Induction of apoptosis by intracellular signals; Negative regulation of cell proliferation                                       ·Protein binding
  Hs.494985             FBXW2                   F-box and WD-40 domain protein 2                97.45      68.65        0.379       40.27          58.47         0     23.54    51.61   0.111   69.32    28.36                                                                       Proteolysis                                                                        Protein binding; ubiquitin conjugating enzyme activity; ubiquitin-protein ligase activity

Mean: Mean gene expression, CV: Coefficient of Variation (%), 0\'s P: 0\'s proportion, GO terms were searched in the Gene Ontology site (<http://www.geneontology.org/>).

The gene expression for each of the 13 nERGs showed a significant correlation between datasets (*P*\<0.001, [Table S6](#pone.0006162.s008){ref-type="supplementary-material"}) with high Pearson correlation coefficients (\>0.8), although the Spearman correlations of EST versus Affymetrix (0.374, *P* = 0.206) and shortSAGE versus Affymetrix (0.511, *P* = 0.076) were not significant. CVs between the datasets were not significantly correlated (*P*\>0.05, [Table S6](#pone.0006162.s008){ref-type="supplementary-material"}).

To further confirm the suitability of the nERGs, gene copy number variations (CNVs) of the nERGs, which can affect the gene expression, were investigated by searching the Database of Genomic Variants. As shown in [Table 4](#pone-0006162-t004){ref-type="table"}, only *OAZ1* and *DIMT1L* were found to be located in a chromosome region where CNVs were reported, indicating their expression might be deregulated by genomic aberrations.

10.1371/journal.pone.0006162.t004

###### Gene copy number variations of nERGs and tERGs.
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  nERGs      tERGs                                                                                                                                                   
  -------- ---------- ------------- ---------- -------------------- ------------------------- -------------------- ------------------------------------------ ------ -------------------
  ZNF207    17q11.2       RPLP0      12q24.23                                                                                                                        
  OAZ1      19p13.3    Copy number     3199     Wong et al (2007)             ACTB                   7p22.1                       Copy number                  1487   Wong et al (2007)
  LUC7L2      7q34        PPIA         7p13                                                                                                                          
  CTBP1      4p16.3       GAPDH      12p13.31      Copy number                2368             Redon et al (2006)                                                    
  TRIM27     6p22.1                    PGK1           Xq21.1               Copy number                3567                    Iafrate et al (2004)                   
  GPBP1      5q11.2                    B2M           15q21.1               Copy number                2773                    Redon et al. (2006)                    
  UBQLN1    9q21.33                    GUSB          7q11.21                                                                                                         
  ARL8B      3p26.1                   HPRT1           Xq26.2                                                                                                         
  PAPOLA    14q32.2                    TBP             6q27                Copy number                1479                     Redon et al (2006)                    
  CUL1       7q36.1                    TFRC            3q29          Copy number Copy number          753           Iafrate et al (2004) Redon et al. (2006)         
  DIMT1L     5q12.1    Copy number     1137     Redon et al (2006)            HMBS                  11q23.3                                                          
  FBXW2      9q33.2                    H6PD          1p36.22                                                                                                         
  SPG21     15q22.31                  ALAS1           3p21.2               Copy number                590                      Wong et al (2007)                     

Genomic location was found using Ensembl (<http://www.ensembl.org/index.html>).

Genomic variations were found using the Database of Genomic Variants (<http://projects.tcag.ca/variation/>, Human Genome Assembly Build 36 (hg18)).

Comparison of tERGs and nERGs in dataset {#s3c}
----------------------------------------

We compared the 13 nERGs with 13 commonly used tERGs: *GAPDH, ACTB, HPRT1, PPIA, B2M, TBP, HMBS, RPLP0, PGK1, GUSB, TFRC, H6PD*, and *ALAS1*. The mean expression of the nERGs was relatively lower than the highly expressed tERGs, including *GAPDH, ACTB, B2M*, and *PPIA*, in all datasets and was expressed at levels similar to those tERGs, which had lower expression levels ([Figure 3](#pone-0006162-g003){ref-type="fig"}, [Table S7](#pone.0006162.s009){ref-type="supplementary-material"}). With respect to variation, most of the tERGs showed relatively higher variation than the nERGs and the mean CV values of nERGs were significantly lower than those of tERGs (*P*\<0.001 in EST, ShortSAGE, and Affymetrix, *P* = 0.003 in LongSAGE, [Table S8](#pone.0006162.s010){ref-type="supplementary-material"}), supporting the notion that the identified nERGs are generally expressed more stably and at relatively lower levels than tERGs.

![Comparison of gene expression and CV between nERGs and tERGs in each dataset.\
(A) Comparison of gene expression between 13 nERGs and 13 tERGs. (B) Comparison of CV between 13 nERGs and 13 tERGs. Empty squares represent nERGs identified in this study and circles represent the tERGs.](pone.0006162.g003){#pone-0006162-g003}

A search for genomic variation of tERGs revealed that many of them (*ACTB, GAPDH, PGK1, B2M, TBP, TFRC, ALAS1*) were located in the genomic locus where CNVs are known, whereas only 2 genes among the nERGs were found in those regions ([Table 4](#pone-0006162-t004){ref-type="table"}), suggesting that the higher expression variation of some tERGs might be due in part to CNVs.

Validation of nERGs by qRT-PCR {#s3d}
------------------------------

To validate both the level and stability of gene expression of nERGs selected from the four datasets, the expression of 13 nERGs and 8 tERGs was measured in a total of 108 human samples, including 26 frozen tissues, 22 cancer cell lines and 60 FFPE tissues, by qRT-PCR using Taqman probes (refer to [Text S1](#pone.0006162.s001){ref-type="supplementary-material"} for an explanation for why 8 tERGs among 13 tERGs were chosen for qRT-PCR). Except *PPIA*, a small amplicon for each gene was designed for the reliable measurement of its expression, especially in FFPE tissues where RNA from these samples is frequently degraded. When the PCR efficiency of each gene was determined using the serial dilution method, each gene was amplified at 90--100% efficiency ([Table 1](#pone-0006162-t001){ref-type="table"}). The CVs of Cp values confirmed that the between-assay precision in two or three repeats was within 5% (data not shown).

First, the expression profiles of these genes in each of the 48 samples, including frozen tissues and cancer cell lines, are presented in [Figure 4A](#pone-0006162-g004){ref-type="fig"}. The 13 nERGs were constitutively expressed in all 48 samples. Seven tERGs showed a wide range of expression (Cp: 13.52 to 29.39), but *H6PD* was not widely expressed in frozen tissues and this gene was consequently excluded from subsequent calculations. The Cp values of 13 nERGs ranged from 18.90 to 28.79 ([Figure 4B](#pone-0006162-g004){ref-type="fig"}). tERGs could be divided into highly expressed genes (median \<20 cycles) and lowly expressed genes (median\>23 cycles). Highly expressed genes included *B2M, PPIA, GAPDH, ACTB* and lowly expressed genes consisted of *HPRT1, TBP* and *HMBS*. Of the nERGs, 12 genes displayed an intermediate expression level between the highly expressed and the lowly expressed tERGs ([Figure 4B](#pone-0006162-g004){ref-type="fig"}). The mean expression level of nERGs was significantly lower than that of highly expressed tERGs, whereas it was significantly higher than that of lowly expressed tERGs (*P*\<0.001, [Table S9](#pone.0006162.s011){ref-type="supplementary-material"}). *ZNF207* was the most highly expressed gene, followed by *UBQLN1* and *CUL1*. *OAZ1* was the gene with the weakest expression.

![The distribution of expression levels of 13 nERGs and 7 tERGs determined by qRT-PCR using Taqman probes in human samples.\
(A) The distribution of mRNA levels of tested ERGs in 48 samples, including frozen tissues and cancer cell lines. (B) The mRNA levels of tERGs (red) and nERGs (blue) in Cp values over all 48 samples (left) and 60 FFPE tissues (right). Values are given as "Crossing point" (Cp) values. All measurements of qRT-PCR were repeated three times for frozen tissues and cell lines and twice for FFPE tissues and mean "crossing point" (Cp) values of repeats were calculated. Box and Whisker plots provide a simple description of the distribution of values by depicting the 25^th^ and 75^th^ percentile values as the bottom and top of the box, respectively. The median value is marked by a line within the box and the minimum and maximum values are depicted by error bars, or whiskers, protruding from the box.](pone.0006162.g004){#pone-0006162-g004}

We further investigated the expression of the 13 nERGs by qRT-PCR in 60 FFPE tissues to test whether the nERGs could be used in such tissues showing the significant degradation of mRNA. Except *DIMT1L*, the expression of all genes was measurable in all 60 samples. The Cp range for tERGs was 18.85 to 33.02 and for nERGs was 23.33 to 31.58 ([Figure 4B](#pone-0006162-g004){ref-type="fig"}). *DIMT1L* was not amplified in 5 samples and therefore was excluded from further expression stability analysis. The expression pattern in the FFPE tissues was similar to that of previous 48 samples (26 frozen tissues and 22 cancer lines) despite the discrepancy in sample types. Remarkably, *PPIA* expression which was detected at high level in frozen tissues/cell lines was observed at markedly decreased level in FFPE tissues. This observation might be due to the long amplicon size of *PPIA* (326 bp), whereas the amplicon size of other genes is small ranging from 60 to 110 bp ([Table 1](#pone-0006162-t001){ref-type="table"}), indicating that small size of amplicon is required for the detection of gene expression in FFPE tissues in which RNA is frequently degraded.

Gene expression stability of nERGs {#s3e}
----------------------------------

We first assessed the gene expression stability (detailed in [Text S1](#pone.0006162.s001){ref-type="supplementary-material"}) in 48 samples, including 26 frozen tissues and 22 cell lines based on qRT-PCR using two programs, geNorm and NormFinder. All genes tested displayed relatively high expression stability with low M values (\<0.9), which were below the default limit of 1.5 in geNorm ([Table 5a](#pone-0006162-t005){ref-type="table"}). *GPBP1* and *CUL1* were identified as the two most stable genes. *B2M* was the least stable gene and had the highest M value (0.888), followed by *ACTB* (0.843), *HMBS* (0.815), and *GAPDH* (0.793). When calculated by NormFinder, *TBP* and *PAPOLA* were the two most stable genes (i.e. having the lowest S values) ([Table 5a](#pone-0006162-t005){ref-type="table"}). Similar to the results from geNorm, tERGs including *B2M, ACTB, GAPDH, HMBS* and *HPRT1*, were found to have less stable expression than nERGs. The mean gene expression stability values in nERGs by geNorm and NormFinder were significantly lower than those in tERGs in both 48 samples and 60 FFPE tissues (*P*\<0.05, [Tables S10](#pone.0006162.s012){ref-type="supplementary-material"}). Both analyses demonstrated that most nERGs showed relatively higher expression stability compared to tERGs, suggesting that nERGs are more suitable for normalization. Moreover, even when gene expression stability was analyzed with relative expression level calculated by PCR efficiencies using the LinRegPCR program, most of nERGs showed a more stable expression than tERGs (data not shown).

10.1371/journal.pone.0006162.t005

###### nERGs and tERGs ranked according to their expression stability, as calculated by the two programs, geNorm and NormFinder, based on qRT-PCR data in 48 frozen tissues/cell lines and 60 FFPE tissues.

![](pone.0006162.t005){#pone-0006162-t005-5}

  \(a\) 48 frozen tissues/cell lines    \(b\) 60 FFPE tissues                                             
  ------------------------------------ ----------------------- -------- ------- -------- ------- -------- -------
  GPBP1                                         0.496            TBP     0.276   GPBP1    0.409   ARL8B    0.233
  CUL1                                                          PAPOLA   0.28    PAPOLA           LUC7L2   0.235
  PAPOLA                                        0.536            CUL1    0.287   ARL8B    0.437    OAZ1    0.247
  TBP                                           0.548           LUC7L2   0.29    CTBP1    0.454   CTBP1    0.251
  LUC7L2                                        0.565           CTBP1    0.312   LUC7L2   0.483   UBQLN1   0.273
  TRIM27                                        0.585           GPBP1    0.317   SPG21    0.509   SPG21    0.28
  FBXW2                                         0.597           TRIM27   0.317   FBXW2    0.528   FBXW2    0.286
  CTBP1                                         0.608           FBXW2    0.329    OAZ1    0.545   PAPOLA   0.29
  UBQLN1                                        0.623           DIMT1L   0.364   UBQLN1   0.555   TRIM27   0.327
  DIMT1L                                        0.637            PPIA    0.383   TRIM27   0.567   GPBP1    0.345
  PPIA                                          0.661           UBQLN1   0.398    TBP     0.58    HPRT1    0.368
  OAZ1                                          0.682            OAZ1    0.438    CUL1    0.593    CUL1    0.383
  ZNF207                                        0.709           ARL8B    0.494   HPRT1    0.609    TBP     0.402
  ARL8B                                         0.731           SPG21    0.502   ZNF207   0.625    HMBS    0.407
  SPG21                                         0.749           ZNF207   0.502    HMBS    0.641   ZNF207   0.44
  HPRT1                                         0.77            HPRT1    0.516   GAPDH    0.668    PPIA    0.461
  GAPDH                                         0.793            HMBS    0.587    PPIA    0.692   GAPDH    0.527
  HMBS                                          0.815           GAPDH    0.591    B2M     0.715    B2M     0.53
  ACTB                                          0.843            ACTB    0.618    ACTB    0.737    ACTB    0.541
  B2M                                           0.888            B2M     0.815                            

Low average expression stability value M and stability value S indicate the high expression stability.

Pearson correlation analysis revealed the higher concordance of both M and S values with CVs in the EST and shortSAGE ([Table 6](#pone-0006162-t006){ref-type="table"}) than in the Affymetrix. High correlation between M and S (Pearson correlation: 0.953, *P*\<0.001) was also observed, indicating that both analyses produced similar results.

10.1371/journal.pone.0006162.t006

###### Correlation between gene expression stability of nERGs and tERGs from qRT-PCR data and CV from each dataset.
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  ---------------------------------- ------- --------- ------------- ------------- ------------ ------------ -------- -------- ---------
  **48 frozen tissues/cell lines**                                                                                             
                                      EST-M    EST-S    ShortSAGE-M   ShortSAGE-S   LongSAGE-M   LongSAGE-S   Affy-M   Affy-S     M-S
  Pearson                             0.676    0.792       0.659         0.75         0.427        0.561      0.039    0.017     0.953
  *P* value                           0.001   \<0.001      0.002        \<0.001       0.061         0.01      0.869    0.944    \<0.001
  Spearman                            0.589    0.605       0.277         0.268        0.092        0.105      0.424    0.357     0.955
  *P* value                           0.006    0.005       0.237         0.254        0.701        0.661      0.063    0.123    \<0.001
  **60 FFPE tissues**                                                                                                          
                                      EST-M    EST-S    ShortSAGE-M   ShortSAGE-S   LongSAGE-M   LongSAGE-S   Affy-M   Affy-S     M-S
  Pearson                             0.623    0.626       0.656         0.737        0.481        0.672      0.243    0.335     0.852
  *P* value                           0.004    0.004       0.002        \<0.001       0.037        0.002      0.317    0.161    \<0.001
  Spearman                            0.663    0.596       0.515         0.502        0.374        0.567      0.521    0.583     0.841
  *P* value                           0.002    0.008       0.024         0.03         0.115        0.013      0.022    0.009    \<0.001
  ---------------------------------- ------- --------- ------------- ------------- ------------ ------------ -------- -------- ---------

M: average expression stability calculated by the geNorm program, S: stability value calculated by the NormFinder program. For 48 samples, 20 reference genes including 13 novel genes and 7 classical genes, were used in the correlation analysis. For 60 FFPE tissues, 19 reference genes excluding DIMT1L were included in the analysis.

Consistently with frozen tissues and cell lines, both gene expression stability values demonstrated that most nERGs with low stability values are superior to tERGs in terms of expression stability in FFPE tissues ([Table 5b](#pone-0006162-t005){ref-type="table"}), proving the usefulness of our nERGs as reliable measurements of gene expression in those tissues. *GPBP1* and *PAPOLA* were the two least variable genes in geNorm and *ARL8B* and *LUC7L2* were the top two ranked genes in NormFinder. However, in the analysis by each tissue, *FBXW2, TRIM27*, and *CUL1* showed high stability values in breast, ovary, and stomach, respectively ([Table 7](#pone-0006162-t007){ref-type="table"}), suggesting that they have high expression variation in each tissue. Also, S values by NormFinder in the ovary and stomach FFPE tissues were calculated based on the combination of intra- and inter-group variations between normal and tumor samples. The relatively high S values of *TRIM27* in the ovary and *CUL1* in the stomach suggest that their expression might be regulated in specific tumors compared to their normal tissues.

10.1371/journal.pone.0006162.t007

###### nERGs and tERGs ranked according to their expression stability, as calculated by the two programs, geNorm and NormFinder, based on qRT-PCR data in each tissue type of FFPE tissues.
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  Breast FFPE (n = 10)    Ovary FFPE (n = 33)[\*](#nt113){ref-type="table-fn"}   Stomach FFPE (n = 17)[\*](#nt113){ref-type="table-fn"}                                                                                                                                         
  ---------------------- ------------------------------------------------------ -------------------------------------------------------- ------- ------------------------------- ----------------- -------- ------------------------------- ------------------ ------- -------- -------
  TBP                                            0.186                                                   LUC7L2                           0.080               ARL8B                    0.336        ARL8B                0.050                    CTBP1         0.296    OAZ1    0.097
  CTBP1                                                                                                  UBQLN1                           0.138               FBXW2                                 SPG21                0.072                    TRIM27                 HMBS    0.123
  PAPOLA                                         0.199                                                   CTBP1                            0.152               CTBP1                    0.361        UBQLN1               0.091                    FBXW2         0.325   FBXW2    0.162
  OAZ1                                           0.231                                                    CUL1                            0.153               SPG21                    0.390        CTBP1                0.110                    LUC7L2        0.354   PAPOLA   0.171
  CUL1                                           0.245                                                    TBP                             0.173              UBQLN1                    0.409        FBXW2                0.114                     OAZ1         0.387   TRIM27   0.200
  ARL8B                                          0.265                                                   SPG21                            0.190              LUC7L2                    0.417        HPRT1                0.117                     HMBS         0.406    B2M     0.202
  GPBP1                                          0.282                                                    B2M                             0.212               OAZ1                     0.436         TBP                 0.129                    GPBP1         0.430   GAPDH    0.207
  UBQLN1                                         0.298                                                    OAZ1                            0.216              PAPOLA                    0.464        LUC7L2               0.131                    PAPOLA        0.446   LUC7L2   0.216
  LUC7L2                                         0.307                                                   ARL8B                            0.219               GPBP1                    0.482         CUL1                0.165                    ARL8B         0.464   ARL8B    0.226
  ZNF207                                         0.317                                                   GPBP1                            0.222               CUL1                     0.498         OAZ1                0.177                     TBP          0.483   ZNF207   0.230
  B2M                                            0.335                                                    HMBS                            0.240                TBP                     0.515        GPBP1                0.184                    ZNF207        0.512    ACTB    0.266
  SPG21                                          0.356                                                   PAPOLA                           0.246              ZNF207                    0.535         PPIA                0.212                    UBQLN1        0.533    PPIA    0.275
  HMBS                                           0.374                                                   TRIM27                           0.253               HPRT1                    0.556        PAPOLA               0.248                    GAPDH         0.556   UBQLN1   0.285
  TRIM27                                         0.389                                                   ZNF207                           0.305              TRIM27                    0.572        ZNF207               0.253                    SPG21         0.575   CTBP1    0.288
  PPIA                                           0.417                                                    ACTB                            0.316               HMBS                     0.590         B2M                 0.285                    HPRT1         0.592   SPG21    0.293
  ACTB                                           0.438                                                    PPIA                            0.317               PPIA                     0.620         HMBS                0.323                     B2M          0.614   GPBP1    0.298
  HPRT1                                          0.464                                                   HPRT1                            0.392                B2M                     0.645        TRIM27               0.326                     PPIA         0.635    TBP     0.336
  FBXW2                                          0.489                                                   FBXW2                            0.447               GAPDH                    0.674         ACTB                0.466                     ACTB         0.657    CUL1    0.342
  GAPDH                                          0.530                                                   GAPDH                            0.570               ACTB                     0.705        GAPDH                0.496                     CUL1         0.682   HPRT1    0.354
                                                                                                                                                  Best combination of two genes   ARL8B and SPG21   0.043    Best combination of two genes   CTBP1 and UBQLN1   0.066           

Gene expression stability S by NormFinder was calculated as an estimate of the combined intra and intergroup variation between normal and tumor tissues. For ovary tissues (n = 33), 10 normal and 23 tumor tissues were included and 17 stomach tissues, including normal (n = 8) and tumor (n = 9) tissues, were used in the analysis.

Low average expression stability M and stability value S indicate the high expression stability.

The optimal number of ERGs for normalization was determined using geNorm. In both the 48 human frozen and cell line samples and 60 FFPE tissues, the optimal number of nERGs required for normalization was fewer than when using tERGs ([Figure 5](#pone-0006162-g005){ref-type="fig"}). Four tERGs and three nERGs were calculated as the optimal number of ERGs needed in the 48 samples when using a V of 0.15 as the cut-off value [@pone.0006162-Vandesompele1]. In the FFPE samples, V2/3 was under 0.15 when using nERGs, suggesting that only two genes are sufficient for optimal normalization, whereas four of seven tERGs were necessary for accurate normalization. This indicates that fewer ERGs are required for optimal normalization when using our nERGs rather than using tERGs.

![Optimal number of ERGs for normalization calculated by the geNorm program.\
Variable V defines the pair-wise variation between two sequential normalization factors containing an increasing number of genes. For example, V2/3 indicates the variation of the normalization factor of two genes in relation to three genes. A large V indicates that the added gene should be included for calculation of the normalization factor. 0.15 was proposed as a cut-off value, below which the inclusion of an additional reference gene is not required. Pair-wise variation analysis to determine the number of ERGs required for accurate normalization was performed in 48 samples including human frozen tissues and cell lines (A), 60 FFPE tissues (B), 33 ovary FFPE tissues (C) and 17 stomach FFPE tissues (D). For each case, the analysis was done for total ERGs, tERGs and nERGs.](pone.0006162.g005){#pone-0006162-g005}

Discussion {#s4}
==========

In the present study, we identified nERGs in human samples using a comparative analysis of different large datasets of human gene expression profiles, while previous attempts to identify nERGs that are superior to tERGs were limited to the analysis of a microarray [@pone.0006162-Hamalainen1], [@pone.0006162-Hoerndli1]--[@pone.0006162-Shulzhenko1] or EST data [@pone.0006162-Coker1].

Candidate HKGs were first selected and included 2,087 genes, which is a larger number of genes than previously identified by other groups [@pone.0006162-Eisenberg1], [@pone.0006162-Hsiao1], [@pone.0006162-Warrington1]. Their characteristics, including high levels of expression [@pone.0006162-Eisenberg1], [@pone.0006162-Warrington1] and the prevalence of CpG islands in the promoter regions [@pone.0006162-Larsen1], [@pone.0006162-Ponger1], were in line with previous studies based on smaller numbers of HKGs, reflecting that "real" HKGs showing constitutive expressions in all tissues are enriched in our list. Thus, this list can be used as a reliable source for the study of HKGs.

The 13 nERGs further identified from candidate HKGs showed relatively lower CV and lower expression than most of the tERGs in all datasets. These findings were further confirmed by qRT-PCR using frozen tissues and cell lines. Generally, the expression of 13 nERGs was lower than the highly expressed tERGs and higher or similar to the weakly expressed tERGs. The expression stability values of the nERGs calculated by both programs also demonstrated that nERGs are generally more stably expressed than tERGs. Although there were slight differences in their rankings between the two programs, *PAPOLA, CUL1, TBP, LUC7L2, GPBP1* and *TRIM27* were found to be the genes with the most stable expression in 48 samples. The observation that *TBP* is one of the most stable genes is not surprising because relatively lower variability of TBP among traditional ERGs was already expected in datasets including EST and ShortSAGE ([Figure 3](#pone-0006162-g003){ref-type="fig"}). On the other hand, our data further supported the unsuitability of the most commonly used ERGs, like *GAPDH, ACTB,* for normalization, in line with previous works [@pone.0006162-Zhong1], [@pone.0006162-Selvey1], [@pone.0006162-Goidin1].

Our nERGs were also successfully validated by qRT-PCR in FFPE tissues. Despite the usefulness of archival FFPE tissue specimens in conjunction with clinical data, frequent degradation of RNA from FFPE tissues has been regarded as an obstacle in the gene expression analysis of those samples [@pone.0006162-Bibikova1]. The expression of nERGs was measurable with reliable Cp values in all 60 FFPE tissues and most of the nERGs outperformed tERGs with respect to expression stability.

Furthermore, the expression level of target gene can be calculated relative to the expression level of one or multiple nERGs using standard curve or comparative Ct(Cp) method in quantitative gene expression analyses, including qRT-PCR. The most suitable ERG or ERGs in the designed experiment can be selected among 13 nERGs or combination of tERGs and 13 nERGs based on gene expression stability values calculated by the geNorm and/or NormFinder program. Recently developed PCR array, high throughput gene expression measurement using qRT-PCR, also requires more suitable ERGs than conventional tERGs for accurate quantification of gene expression [@pone.0006162-Spurgeon1]. Recently, normalization using the geometric mean of multiple ERGs has been considered to be more accurate for normalization [@pone.0006162-Vandesompele1], especially in situations when no optimal ERG has been identified [@pone.0006162-Andersen1]. Moreover, the use of multiple ERGs is more important in the expression analysis using FFPE tissues, where poor RNA quality causes additional variations in gene expression [@pone.0006162-Glenn1]. Five tERGs are included for the normalization of gene expression in the Onco*type* DX™ assay (Genomic Health) which is a clinical validated multigene qRT-PCR test using FFPE tissues to predict recurrence of breast cancer [@pone.0006162-Paik1]. However, the superiority of our nERGs was demonstrated by showing that a fewer number of genes is required for normalization when using the nERGs as compared with using the tERGs. Considering the limited amounts of samples or experiment cost, nERGs also outperformed previous tERGs when multiple genes are needed for reliable normalization. Taken together, nERGs will be a better choice for more reliable normalization in gene expression analysis using FFPE tissues.

The superiority of nERGs over tERGs is based in their lower expression level as well as their high expression stability. Use of ERGs with expression levels similar to target genes is recommended so that the comparisons fall on the same linear scale [@pone.0006162-Czechowski1], [@pone.0006162-Szabo1], [@pone.0006162-RocheAppliedScience1]. Therefore, our nERGs, with relatively lower expression, rather than *GAPDH* or *ACTB* showing high expression, can be better candidates for normalization of a wide range of genes, including weakly expressed genes. This is significant given that the majority of transcripts in human tissues are expressed in low abundance [@pone.0006162-Warrington1].

Remarkably, we observed no significant correlation between the stability values calculated from qRT-PCR data and CV in the Affymetrix data, which is in contrast to the significant correlation between stability values and CV in the EST and SAGE dataset. This suggests that EST or shortSAGE may be better sources for exploring nERGs rather than microarrays, which have traditionally been used as a source for screening ERG and supports our initial hypothesis that the microarray might not be a good source for ERGs.

Furthermore, nERGs identified here might be used as reference for relative measurements of gene amplification, which is a frequent genetic alteration leading to unregulated gene expression in cancer [@pone.0006162-Lehmann1]. As the relatively constant expression of these genes in both normal and tumor tissues provides the possibility that these genes are located in a chromosomal region in which no genetic alterations are found in human tumors, we investigated the genomic CNVs of nERGs using publicly available databases. Most nERGs, except *OAZ1* and *DIMT1L,* were located in genomic regions where CNVs were not reported, whereas many tERGs were located in regions with CNVs. The relatively lower expression stability of *OAZ1* and *DIMT1L*, as well as tERGs like *GAPDH* and *ACTB*, might be explained by these genomic aberrations. However, the suitability of nERGs as a reference for the relative measurement of gene amplification remains to be further investigated and validated through experiments. Meanwhile, even genes with genomic variations can be used for the normalization in gene expression, provided that their expression is not affected by genomic aberrations.

In conclusion, we have identified a set of candidate HKGs and nERGs based on a comparative analysis of EST, SAGE, and Affymetrix datasets. This is the first study using three different platforms to identify nERGs, and most of the 13 ERGs identified in these datasets were demonstrated to be more stably expressed than tERGs through the validation using qRT-PCR in large human samples including cell lines, frozen tissues and FFPE tissues. Moreover, these nERGs were expressed at relatively lower levels than most commonly used high expressing tERGs, making them more suitable for normalization of transcripts from a wide range of expression levels. We have also shown that fewer ERGs are required for accurate normalization using nERGs than using tERGs, especially in FFPE tissues when the use of multiple ERGs is required.
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